GENE ONLINE|News &
Opinion
Blog

2022-11-24| Partnerships

Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug

by Joy Lin
Share To

Novartis and its partner Medicines for Malaria Venture (MMV) are taking their non-artemisinin combination, ganaplacide/lumefantrine, into Phase 3 development for the treatment of uncomplicated malaria caused by Plasmodium falciparum. 

According to the most recent World Malaria Report released last December, there were approximately 241 million cases of malaria and 627,000 deaths worldwide in 2020. 

While artemisinin-based combination therapies (ACT) are still highly effective in treating malaria, the increasing prevalence of parasites with a slower response to artemisinin has been observed in parts of Africa. 

Related Article: Extreme Climate Change Is Aggravating Infectious Diseases!

Pivotal Trial For Non-Artemisinin Alternative

Novartis is testing a novel agent called ganaplacide, which is combined with a new solid dispersion formula (SDF) of lumefantrine that is optimized for once-daily dosing. According to Novartis, ganaplacide works via a new mechanism of action. The non-artemisinin combination is designed to attack the malaria parasite, including those resistant to artemisinin, on two fronts —to clear infection and block transmission of the parasite. 

The combination was tested in a Phase 2 study which enrolled 524 adults and children with acute uncomplicated malaria. The trial reached its primary endpoint, showing that the response rate of patients treated with once-daily ganaplacide/lumefantrine for three days was similar to the rate observed in patients treated with twice-daily artemether-lumefantrine in the same period. Artemether-lumefantrine (Coartem) is a “gold standard” treatment for malaria. 

The pivotal Phase 3 will start in 2023 and will compare ganaplacide/lumefantrine-SDF to artemether-lumefantrine, Novartis said. The trial will be conducted with the WANECAM 2 consortium, a West African network for clinical trials of antimalarials, and will include partner clinical sites in Burkina Faso, Mali, Gabon, Niger, and sub-Saharan Africa. The study, like its Phase 2 predecessor, is funded by the European and Developing Countries Clinical Trials Partnership (EDCTP), supported by the European Union. 

“If the Phase 3 trial is successful, this new combination will increase the number of options available to countries and help save the lives of children at risk of this devastating disease,” said Dr. Timothy Wells, the Chief Scientific Officer of MMV. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Novartis Secures Approval for First-Ever Malaria Treatment Designed for Newborns After a Decade of Research
2025-07-09
What’s Next for Emerging Biotechs? Investment and R&D Insights from BIO 2025
2025-06-18
Biotech Stocks Rise Following Federal Reserve Rate Outlook
2025-03-21
LATEST
University of Pittsburgh Study Finds Flu Vaccines Prevent Up to 41.5 Percent of Infections in Simulated Communities
2025-07-19
Pharmacist-Led Initiatives Boost Pneumococcal Vaccine Uptake Among Older Adults Through Education and Direct Immunization Services
2025-07-19
Study Finds Agricultural Dust Exposure Alters Gut Microbiota and Weakens Intestinal Barrier in Mice
2025-07-19
Biotech Leaders Urge FDA to Reject Conservative Report Criticizing Mifepristone Safety Profile
2025-07-19
Physician Calls for Better Diagnosis of Cannabinoid Hyperemesis Syndrome Amid Discussions on Drug Pricing and Accessibility
2025-07-19
Maternal Vaccination Linked to Reduced RSV Hospitalizations in Newborns
2025-07-18
FDA Advisory Committee Votes Against Approval of GSK’s Blenrep Ahead of PDUFA Date
2025-07-18
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top